1Fahimi F, Ghafari S, Jamaati H,et al. Continuous versus intermit-tent administration of piperacillin-tazobactam in intensive care u-nit patients with ventilator-associated pneumonia. Indian J CritCare Med,2012 ,16(3 ) : 141-147.
2Uchida T,Sugino Y,Hazekawa M,et al. Factors affecting the bit-terness intensities of ten commercial formulations of ambroxol.Chem Pharm Bull (Tokyo) ,2012,60(8) : 949-954.
3Tuzgen S, Kucukyuruk B, Aydin S, et al. Decompressive craniec-tomy in patients with cerebral infarction due to malignant vaso-spasm after aneurysmal subarachnoid hemorrhage. J Neurosci Ru-ral Pract,2012,3(3) :251-255.
4Garcia-Elorriaga G,Padilla-Reyes M, Cruz-Olivo F,et al. Pro-in-flammatory cytokines related to severity and mortality in type 2 di-abetes patients with soft tissue infection. Rev Med Inst Mex Segii-ro Soc,2012,50(3) :237-241.
5Paleari D, Rossi GA, Nicolini G, et al. Ambroxol: a multifacetedmolecule with additional therapeutic potentials in respiratory dis-orders of childhood. Expert Opin Drug Discov,2011 ,6(11):1203-1214.
6Al-Lawati JA, N Barakat M, Al-Zakwani I, et al. Control of riskfactors for cardiovascular disease among adults with previously di-agnosed type 2 diabetes mellitus : a descriptive study from a mid-dle eastern arab population. Open Cardiovasc Med J, 2012, 21(6):133-140.
7Gao X,Huang Y,Han Y,et al. The protective effects of Ambroxolin Pseudomonas aeruginosa-induced pneumonia in rats. Arch MedSci,2011,7(3) :405413.
